Related Experiment Video
Updated: Feb 16, 2026

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
Published on: May 10, 2022
Erythroferrone and iron status parameters levels in pediatric patients with iron deficiency anemia
Fady M El Gendy1, Mahmoud A El-Hawy1, Amira M F Shehata2
1Pediatrics Department, Faculty of Medicine, Menoufia University, Shebin El Kom, Menoufia, Egypt.
Insights
Serum erythroferrone (ERFE) levels are significantly higher in children with iron deficiency anemia. ERFE may suppress hepcidin, offering a potential therapeutic target for anemia.
Area of Science:
- Pediatric Hematology
- Iron Metabolism
- Hormonal Regulation
Background:
- Iron deficiency anemia (IDA) is a prevalent condition in children.
- Erythroferrone (ERFE) is a recently identified hormone involved in iron regulation.
- Understanding ERFE's role in IDA is crucial for developing new therapies.
Purpose of the Study:
- To investigate the association between serum ERFE levels and iron status in pediatric IDA.
- To explore the correlation of ERFE with key iron parameters like hemoglobin, ferritin, serum iron, transferrin saturation, and TIBC.
Main Methods:
- A cohort of 66 children, including 36 with IDA and 30 healthy controls, was studied.
- Serum levels of iron, total iron-binding capacity (TIBC), ferritin, and ERFE were measured.
- Standard automated chemistry analyzers, electrochemiluminescence immunoassay, and ELISA kits were utilized.
Main Results:
- Children with IDA exhibited significantly higher serum ERFE levels compared to controls (191.55 ± 83.74 pg/mL vs. 42.22 ± 16.55 pg/mL, P < .001).
- In IDA patients, ERFE levels negatively correlated with hemoglobin, serum iron, transferrin saturation, and ferritin.
- A positive correlation was found between ERFE and TIBC in IDA patients (r = .62, P < .001).
Conclusions:
- Elevated serum ERFE in pediatric IDA suggests a potential role in iron dysregulation.
- ERFE may function as a physiological suppressor of hepcidin in IDA.
- ERFE presents a promising therapeutic target for managing iron deficiency anemia.
Objectives:
To investigate the link between serum erythroferrone (ERFE) levels and iron status parameters in pediatric patients with iron deficiency anemia.
Methods:
The study consisted of 66 children (36 with iron deficiency anemia and 30 healthy age- and gender-matched controls) who were investigated for serum levels of iron, total iron-binding capacity (TIBC) using automated chemistry analyzer, serum ferritin using electrochemiluminescence immunoassay and ERFE by specific enzyme-linked immunosorbent assay (ELISA) kit.
Results:
Serum erythroferrone levels in iron deficiency anemia patients (191.55 ± 83.74 pg/mL) were significantly higher than those in control group (42.22 ± 16.55 pg/mL) (P < .001). In iron deficiency anemia patients, serum erythroferrone concentrations correlated negatively with hemoglobin concentration (r = -.39; P = .01), serum iron (r = -.63; P < .001), transferrin saturation (r = -.66; P < .001), and serum ferritin (r = -.46; P = .004) while positive correlation was observed between serum erythroferrone concentrations and TIBC (r = .62; P < .001) CONCLUSION: The newly identified erythroferrone hormone may act as physiological hepcidin suppressor in cases with iron deficiency anemia, and so it may serve as a specific promising target of therapy in such cases.
More Related Videos
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Wave Parameters
Marcia's Theory of Identity Status

